The Trendlines Group Ltd. (TRNGF)
| Previous Close | 0.0564 |
| Open | 0.0564 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0564 - 0.0564 |
| 52 Week Range | 0.0564 - 0.0784 |
| Volume | |
| Avg. Volume | 7 |
| Market Cap | 54.102M |
| Beta (5Y Monthly) | 0.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswireVessi Medical Closes $16.5 Million Series A Round for Innovative Cryotherapy Bladder Cancer Treatment
Vessi Medical Ltd. ("Vessi") announced today that it has closed a Series A financing round of $16.5 million for its cryotherapy technology to treat Non Muscle Invasive Bladder Cancer ("NMIBC"). Leading investors in the round are an undisclosed global strategic investor, ALIVE- Israel HealthTech Fund, and Agriline, a trust of which UK investor Vincent Tchenguiz is a discretionary beneficiary, joining The Trendlines Group.
GlobeNewswireOTC Markets Group Announces the 2024 OTCQX Best 50
NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), today announced the 2024 OTCQX® Best 50, a ranking of the top-performing OTCQX companies in the prior calendar year. The OTCQX Best 50 is an annual ranking of the top 50 U.S. and international companies traded on the OTCQX Best Market, based on an equal weighting of one-year total return and average daily dollar volume growth. Companies in the 2024 OTCQX Best 50 were ranked based on their performance during the 202
